Dengue watch prompts ban on OTC sale of anti-inflammatory meds

Image
Press Trust of India New Delhi
Last Updated : Jul 04 2015 | 7:22 PM IST
Delhi government has decided to ban over-the-counter sale of nonsteroidal anti-inflammatory drugs (NSAIDs) like Aspirin, Dispirin, Brufen, Voveran, etc. From August 15 till November 30 as the use of these, according to experts, may pose a threat to dengue patients.
"NSAIDs drugs (Aspirin, Dispirin, Brufen, Voveran, etc.) will be banned for over-the-counter (OTC) sale by chemists from August 15 till November 30. It will be sold only on the basis of prescription by a qualified doctor.
"According to dengue experts, these drugs may add to the haemorrhage symptoms and can cause death in dengue patients," said a senior Delhi government official.
At a review meeting today, Health Minister Satyendra Jain today directed medical superintendents at all hospitals in the city to procure NS1 Antigen detection kits and also arrange for adequate number of beds during the peak dengue season.
"IgM (Mac ELISA) kits will be provided centrally by NIV, Pune," said the official.
Hospitals have been asked to keep adequate blood and supplies. Besides, all Delhi government hospitals, structures and institutions have been asked to procure mosquito-proof air coolers (MPC) designed by National Centre for Disease Control (NCDC).
"Mosquito bed nets will be made available at each of the 33 Sentinel Surveillance Hospitals.
"Delhi government will also give appreciation certificates to those government hospitals or buildings where no breeding is found while the defaulters would be penalised," said the official.
Jain has also directed that all advisories regarding dengue and its management with respect to government and private hospitals, dispensaries, laboratories and general public be redrafted and simplified.
"The misconception, particularly regarding platelet count, amongst general public and healthcare providers should be clarified in the said advisories," the minister said.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jul 04 2015 | 7:22 PM IST

Next Story